JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 49(2015) N 6 p. 939-942; DOI 10.1134/S0026893315050222 Full Text

T.D. Lebedev, P.V. Spirin, N.N. Orlova, M.M. Prokofjeva, V.S. Prassolov*

Comparative analysis of gene expression: Targeted antitumor therapy in neuroblastoma cell lines

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia

*prassolov45@mail.ru
Received - 2015-01-19; Accepted - 2015-02-17

In this study, we evaluated the level of c-kit, VEGFA, and MYC gene expression in seven neuroblastoma stable cell lines, i.e., SK-N-SH, SK-N-BE, SK-N-AS, SH-SY5Y, Kelly, IMR-32, and LAN-1. The level of expression of these genes can serve as a diagnostic factor for cancer progression and proteins encoded by these genes are promising targets for neuroblastoma treatment. SH-SY5Y and SK-N-AS cells have the highest MYC expression and the same VEGFA expression, although SH-SY5Y has tenfold higher c-kit expression than SK-N-AS cells. Both IMR-32 and LAN-1 cells have low levels of MYC expression, but differ in c-kit expression, while IMR-32 has significantly higher c-kit expression than any other neuroblastoma cell line. On the other hand, LAN-1 has the highest VEGFA expression. These data suggest that MYC, c-kit, and VEGFA genes can play different roles in the development and progression of neuroblastoma depending on other activated molecular mechanisms in malignant cells.

neuroblastoma, malignant cells, angiogenesis, VEGFA, c-kit



JMB-FOOTER RAS-JOURNALS